Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory Follicular Lymphoma
Commercial Sponsor
Regeneron Pharmaceuticals
Summary
This is a single arm study, in which eligible patients will receive REGN1979 by intravenous infusion. The primary objective of this study is to assess the anti-tumor activity of single agent REGN1979, as measured by objective response rate (ORR) according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) by independent central review.